Our drug R&D is supported by scientific research published by the Akero team, our collaborators, and by external experts.
Aug 2022 | From Akero Therapeutics
Normalization of liver fat by efruxifermin is associated with improved liver, adipose tissue, and whole-body metabolic health
Aug 2022 | From Akero Therapeutics
A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis
Jun 2022 | From Akero Therapeutics
Efruxifermin (EFX), a long-acting FGF21 analog as a therapy for NASH

